Article Versions Notes

Yamamoto Y, Teshigawara A, Tamura R, Takei J, Morimoto Y, Tomoto K, Akasaki Y, Hasegawa Y, Murayama Y, Miyake K, et al. Validation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching. Cancers. 2026; 18(3):488. https://doi.org/10.3390/cancers18030488

Yamamoto, Yohei, Akihiko Teshigawara, Ryota Tamura, Jun Takei, Yukina Morimoto, Kyoichi Tomoto, Yasuharu Akasaki, Yuzuru Hasegawa, Yuichi Murayama, Keisuke Miyake, and et al. 2026. "Validation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching" Cancers 18, no. 3: 488. https://doi.org/10.3390/cancers18030488

Yamamoto, Y., Teshigawara, A., Tamura, R., Takei, J., Morimoto, Y., Tomoto, K., Akasaki, Y., Hasegawa, Y., Murayama, Y., Miyake, K., Sasaki, H., & Tanaka, T. (2026). Validation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching. Cancers, 18(3), 488. https://doi.org/10.3390/cancers18030488